PROTAC Degrader

PROTAC degraders recruit an E3 ubiquitin ligase to a target protein so that the proteasome degrades it. Each proteolysis-targeting chimera (PROTAC) links a target-binding ligand to an E3 ligase ligand through a chemical linker. The approach was first described in 2001, and later work showed that small-molecule PROTACs can act catalytically, removing several target copies per molecule. Examples include the bromodomain and extra-terminal (BET) degraders dBET1, MZ1 and ARV-771, and the estrogen receptor degrader ERD-308. Degraders of anti-apoptotic proteins, such as PROTAC Mcl1 degrader-1, are also listed.

Items 601-625 of 824

  • PROTAC EZH2 Degrader-10
    Cat. No.
    A57762

    PROTAC EZH2 Degrader-10

    PROTAC EZH2 Degrader-10 is a Proteolysis Targeting Chimeras (PROTAC) compound designed to selectively degrade the enhancer of zeste homolog 2 (EZH2). By facilitating the ubiquitination and subsequent proteasomal degradation of EZH2, this compound exhibits potential as an innovative therapeutic approach for cancer research. Its mechanism involves a specific ligand for EZH2 and a cereblon ligand, linked together to enhance degradation efficiency, making it a valuable tool for investigating EZH2-related oncogenic pathways.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-35
    Cat. No.
    A57763

    PROTAC EZH2 Degrader-35

    PROTAC EZH2 Degrader-35 is a proteolysis-targeting chimera (PROTAC) specifically designed to degrade the Enhancer of Zeste Homolog 2 (EZH2) protein, exhibiting a binding affinity (Ka) of 16.19 nM. This compound demonstrates significant antiproliferative activity against triple-negative breast cancer cells while maintaining minimal cytotoxicity toward normal human epithelial, hepatic, and renal cells. PROTAC EZH2 Degrader-35 is a valuable tool for studying the role of EZH2 in cancer biology and has potential applications in therapeutic research focused on triple-negative breast cancer.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-27
    Cat. No.
    A57764

    PROTAC EZH2 Degrader-27

    PROTAC EZH2 Degrader-27 is a potent EZH2 PROTAC inhibitor with an IC50 of 4.00 nM, specifically designed to target the SET domain of the EZH2 methyltransferase. By engaging in targeted protein degradation, this compound effectively inhibits methyltransferase activity, leading to downregulation of histone methylation. Research applications include studies on epigenetic regulation and potential therapeutic strategies targeting EZH2 in various cancers.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-13
    Cat. No.
    A57765

    PROTAC EZH2 Degrader-13

    PROTAC EZH2 Degrader-13 is a targeted proteolysis-targeting chimera (PROTAC) designed to selectively degrade Enhancer of Zeste Homolog 2 (EZH2) with an IC50 of 2.70 nM. This compound exhibits potent antiproliferative effects in various cancer cell lines, making it a valuable tool in cancer research. PROTAC EZH2 Degrader-13 facilitates investigations into the role of EZH2 in tumorigenesis and therapeutic resistance, providing insights for the development of innovative cancer treatments.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-23
    Cat. No.
    A57766

    PROTAC EZH2 Degrader-23

    PROTAC EZH2 Degrader-23 is a targeted protein degradant that specifically degrades EZH2 through a PROTAC mechanism. It acts by inhibiting the methyltransferase activity of EZH2 via binding to the SET domain, exhibiting a target IC50 of 30.00 nM. This compound is valuable for research applications focused on the modulation of gene silencing pathways and the exploration of EZH2's role in cancer biology.

    Out of stock

    All 3 sizes
  • MS115
    Cat. No.
    A57767

    MS115

    MS115 is a selective degrader targeting the PRMT5/MEP50 complex, demonstrating DC50 values of 17.4 nM and 11.3 nM for PRMT5 at 24 hours in MDAMB468 breast cancer cells. This compound effectively inhibits the proliferation of breast cancer cells, making it a valuable tool for studying PRMT5-mediated pathways and evaluating therapeutic strategies in cancer research. MS115's unique mechanism positions it as a significant reagent for investigating the roles of epigenetic regulators in tumor biology.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-37
    Cat. No.
    A57768

    PROTAC EZH2 Degrader-37

    PROTAC EZH2 Degrader-37 is a PROTAC compound designed to induce the degradation of the EZH2 protein, exhibiting a target IC50 of 144 nM. This reagent is valuable for research related to lymphomas and other conditions where dysregulation of histone methylation is implicated. Its mechanism harnesses the cellular degradation pathway, providing a potent tool for studying EZH2-dependent biological processes and developing therapeutic strategies against EZH2-driven malignancies.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-28
    Cat. No.
    A57769

    PROTAC EZH2 Degrader-28

    PROTAC EZH2 Degrader-28 is a targeted PROTAC protein degrader designed to selectively degrade the EZH2 enzyme, demonstrating an IC50 of 16.2 μM in diffuse large B-cell lymphoma (DLBCL) cell lines. This compound is valuable for studying the role of EZH2 in lymphoma biology and therapeutic interventions. Its dual-ligand structure combines an EZH2 ligand with a VHL ligand, facilitating targeted protein degradation for advancing cancer research.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-20
    Cat. No.
    A57770

    PROTAC EZH2 Degrader-20

    PROTAC EZH2 Degrader-20 is a small-molecule degrader specifically designed to target the EZH2 protein, utilizing the proteolysis targeting chimera (PROTAC) mechanism. It demonstrates potent antiproliferative effects with an IC50 of approximately 10 μM in lymphoma cell lines. This compound is ideal for research focused on understanding the role of EZH2 in lymphoma and exploring new therapeutic approaches for this malignancy.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-25
    Cat. No.
    A57771

    PROTAC EZH2 Degrader-25

    PROTAC EZH2 Degrader-25 is a proteolysis-targeting chimera (PROTAC) designed to specifically degrade the EZH2 protein through targeted ubiquitination and proteasomal degradation. This compound is valuable for investigating the role of EZH2 in various lymphoma types, facilitating studies on its contribution to tumorigenesis. In addition, it illustrates the potential of PROTAC technology in modulating epigenetic regulators for therapeutic applications.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-16
    Cat. No.
    A57772

    PROTAC EZH2 Degrader-16

    PROTAC EZH2 Degrader-16 is a targeted PROTAC protein degrader that specifically induces the degradation of EZH2, exhibiting an IC50 of 13.74 μM in SU-DHL-6 cells. This compound demonstrates significant antiproliferative activity against diffuse large B-cell lymphoma (DLBCL) cells, making it valuable for research focused on DLBCL. Its unique design incorporates a histone methyltransferase ligand and a Cereblon ligand linked via a proprietary linker, facilitating targeted degradation for therapeutic exploration.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-31
    Cat. No.
    A57773

    PROTAC EZH2 Degrader-31

    PROTAC EZH2 Degrader-31 is a targeted protein degrader that effectively interacts with EZH2, promoting its degradation through the use of a PROTAC strategy. This compound demonstrates potent antiproliferative activity, with IC50 values of 3.63 μM in lSU-DHL-6 cells and 8.74 μM in HBL-1 cells. It is valuable for research focused on lymphoma, offering insights into EZH2-mediated pathways and potential therapeutic interventions.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-14
    Cat. No.
    A57774

    PROTAC EZH2 Degrader-14

    PROTAC EZH2 Degrader-14 is an EZH2-targeting PROTAC degrader that selectively induces degradation of the EZH2 protein. With an IC50 of 18.21 μM, it effectively targets diffuse large B-cell lymphoma cells while showing no antiproliferative effects on non-target cells at concentrations up to 30.00 μM. This compound is valuable for research focused on the role of EZH2 in diffuse large B-cell lymphoma and provides a tool for exploring novel therapeutic strategies in oncology.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-22
    Cat. No.
    A57775

    PROTAC EZH2 Degrader-22

    PROTAC EZH2 Degrader-22 is a PROTAC (Proteolysis Targeting Chimera) designed to target and degrade the EZH2 protein. This compound effectively modulates EZH2 activity, leading to the inhibition of histone methylation and promoting cancer cell apoptosis. It is particularly valuable in cancer-related research, facilitating the study of epigenetic regulation and therapeutic interventions.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-42
    Cat. No.
    A57777

    PROTAC EZH2 Degrader-42

    PROTAC EZH2 Degrader-42 is a targeted degrader that specifically induces degradation of EZH2, a histone methyltransferase, via cIAP-mediated ubiquitination and subsequent proteasomal pathway. This compound exhibits antiproliferative activity and is particularly useful in the study of lymphoma. By modulating EZH2 levels, it provides a valuable tool for investigating epigenetic regulation and related therapeutic strategies in cancer research.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-36
    Cat. No.
    A57778

    PROTAC EZH2 Degrader-36

    PROTAC EZH2 Degrader-36 is a targeted PROTAC designed to degrade the EZH2 protein, exhibiting a target IC50 of 16.00 nM. This compound is particularly relevant for research applications related to lymphoma, leveraging the selective degradation of EZH2 to investigate its role in cancer progression. The molecule consists of a histone methyltransferase ligand, a Cereblon ligand, and a linker, facilitating the ubiquitin-proteasome pathway for protein elimination.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-19
    Cat. No.
    A57779

    PROTAC EZH2 Degrader-19

    PROTAC EZH2 Degrader-19 is a potent PROTAC compound that targets the enhancing zeste homolog 2 (EZH2) with an IC50 of 15.00 nM. This reagent effectively induces degradation of all Polycomb Repressive Complex 2 (PRC2) subunits, including EZH2, SUZ12, EED, and RbAp48, in a concentration- and time-dependent manner. PROTAC EZH2 Degrader-19 demonstrates significant antiproliferative effects in cancer cell lines, making it a valuable tool for cancer research and therapeutic applications.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-34
    Cat. No.
    A57780

    PROTAC EZH2 Degrader-34

    PROTAC EZH2 Degrader-34 is a targeted degrader of EZH2, exhibiting an IC50 of 6.30 μM in human EZH2 inhibition. This compound is designed to selectively induce the degradation of EZH2, a key enzyme involved in histone methylation. Its applications are primarily in the study of malignancies such as Pfeiffer and prostate cancer, facilitating investigations into the molecular mechanisms of oncogenesis and potential therapeutic interventions.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-11
    Cat. No.
    A57781

    PROTAC EZH2 Degrader-11

    PROTAC EZH2 Degrader-11 is a targeted protein degrader designed to selectively degrade the EZH2 protein through a PROTAC mechanism. This compound effectively reduces tumor size and viability in three-dimensional spheroid models, demonstrating potential for cancer research applications. The technology leverages a dual-ligand system, incorporating an EZH2 ligand and a Cereblon ligand, connected by a linker to facilitate the targeted degradation process.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-45
    Cat. No.
    A57782

    PROTAC EZH2 Degrader-45

    PROTAC EZH2 Degrader-45 is a specialized PROTAC protein degrader designed to target EZH2, exhibiting an IC50 of 22.97 μM in SU-DHL-6 cells. This compound is primarily utilized in research focused on diffuse large B-cell lymphoma, providing insights into epigenetic regulation through targeted protein degradation. The product includes a histone methyltransferase ligand and a VHL ligand, linked for enhanced efficacy in cellular studies.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-40
    Cat. No.
    A57783

    PROTAC EZH2 Degrader-40

    PROTAC EZH2 Degrader-40 is a PROTAC protein degrader specifically designed to target the enhancer of zeste homolog 2 (EZH2), exhibiting an IC50 value of 15.35 μM in SU-DHL-6 cells. This compound is valuable for researching diffuse large B-cell lymphoma and related epigenetic mechanisms. Its structure consists of a histone methyltransferase ligand, an aminopeptidase ligand, and a linker, facilitating targeted degradation of EZH2 to explore therapeutic potential in cancer treatment.

    Out of stock

    All 3 sizes
  • PROTAC EZH2 Degrader-29
    Cat. No.
    A57784

    PROTAC EZH2 Degrader-29

    PROTAC EZH2 Degrader-29 is a targeted protein degrader that specifically engages the EZH2 protein, exhibiting an IC50 of 24.53 μM in diffuse large B-cell lymphoma cells. This compound serves as a valuable tool for investigating the degradation of EZH2 in both basic and translational research settings related to diffuse large B-cell lymphoma and other malignancies.

    Out of stock

    All 3 sizes
  • WD6305
    Cat. No.
    A57818

    WD6305

    WD6305 is a selective PROTAC degrader targeting METTL3 and METTL14, with DC50 values of 140 nM and 194 nM, respectively. This compound effectively inhibits m6A modification and has been shown to suppress proliferation and induce apoptosis in acute myeloid leukemia (AML) cells. WD6305 demonstrates significant antitumor activity, making it a valuable tool for research on RNA modifications and cancer therapeutics.

    1 mg
    $175.00
    5 mg
    $445.00
    All 3 sizes
  • WDR5 degrader-1
    Cat. No.
    A57856

    WDR5 degrader-1

    WDR5 Degrader-1 is a cereblon (CRBN)-recruiting compound designed to selectively induce degradation of the WDR5 protein. This degrader effectively targets WDR5 while sparing the CRBN neo-substrate IKZF1, facilitating precise manipulation of WDR5 levels in cellular systems. It is a valuable tool for investigating the biological roles of WDR5 in transcriptional regulation and potential therapeutic strategies in diseases associated with dysregulated WDR5 expression.

    5 mg
    $575.00
    10 mg
    $1,010.00
    All 3 sizes
  • XF067-68
    Cat. No.
    A57860

    XF067-68

    XF067-68 is a PROTAC designed for the targeted degradation of the WD40 repeat domain protein 5 (WDR5). This compound facilitates the specific elimination of WDR5, making it a valuable tool for investigating diseases associated with WDR5 dysregulation. Researchers can employ XF067-68 to elucidate the biological roles of WDR5 and explore potential therapeutic interventions in related disorders.

    5 mg
    $450.00
    10 mg
    $750.00
    All 4 sizes

Items 601-625 of 824

Added to your cart

View Cart Checkout

    Loading...